Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Patients with T1D experienced greater reductions in risk for cardiovascular disease with empagliflozin compared with placebo.

Experts say 85% price drop in empagliflozin expected to boost SGLT2 usage; SGLT-2 class of drugs account for 25-30% of all diabetes prescriptions ...